(Z)-N-(2-oxo-3-(phenyl(4-(piperidin-1-ylmethyl)phenylamino)methylene)-indolin-5-yl)benzenesulfonamide | 422515-40-0

• 分子结构分类: 有机化合物 - 有机杂环化合物 - 哌啶类
• 英文名称: (Z)-N-(2-oxo-3-(phenyl(4-(piperidin-1-ylmethyl)phenylamino)methylene)-indolin-5-yl)benzenesulfonamide
• 英文别名: (Z)-3-(1-(4-(piperidin-1-yl-methyl)-phenylamino)-1-phenyl-methylene)-5-(phenylsulfonylamino)-2-indolinone；N-[(3Z)-2-oxo-3-[phenyl-[4-(piperidin-1-ylmethyl)anilino]methylidene]-1H-indol-5-yl]benzenesulfonamide
• CAS: 422515-40-0
• 化学式: C₃₃H₃₂N₄O₃S
• 分子量: 564.708
• InChiKey: YDZPZHJIXIXGEU-MVJHLKBCSA-N

计算性质

• 辛醇/水分配系数(LogP)：
  6.41
• 重原子数：
  41.0
• 可旋转键数：
  8.0
• 环数：
  6.0
• sp3杂化的碳原子比例：
  0.18
• 拓扑面积：
  90.54
• 氢给体数：
  3.0
• 氢受体数：
  5.0

反应信息

• 作为产物：
  描述：

  5-硝基-1,3-二氢-2H-吲哚-2-酮 在 水 、 氯化铵 、 三乙胺 、 sodium hydroxide 、 锌 作用下， 以 甲醇 、 水 、 N,N-二甲基甲酰胺 为溶剂， 反应 46.5h， 生成 (Z)-N-(2-oxo-3-(phenyl(4-(piperidin-1-ylmethyl)phenylamino)methylene)-indolin-5-yl)benzenesulfonamide
  参考文献：
  名称：

  Repurposing human Aurora kinase inhibitors as leads for anti-protozoan drug discovery

  摘要：

  Hesperadin，一种已知的人类极光B抑制剂，被测试用于Trypanosoma brucei、Leishmania major和Plasmodium falciparum的培养物中，被确认为一种有效的增殖抑制剂。

  DOI：

  10.1039/c4md00045e

文献信息

• Use of Lck inhibitors for treatment of immunologic diseases
  申请人：Boehringer Ingelheim Pharma GmbH & Co. KG

  公开号：US20040204458A1

  公开（公告）日：2004-10-14

  The invention relates to a method of treating immunologic diseases or pathological conditions involving an immunologic component using certain Lck inhibitors already known as kinase inhibitors for therapy in oncology, optionally in combination with one or more other drugs selected from NSAIDs, steroids, DMARDs, immunsuppressives, biologic response modifiers and antinfectives, pharmaceutical compositions comprising said Lck inhibitors together with said other drugs, and the use of the Lck inhibitors for the manufacture of a pharmaceutical composition for the treatment of immunologic diseases or pathological conditions involving an immunologic component.

  该发明涉及一种治疗免疫性疾病或涉及免疫组分的病理条件的方法，使用某些已知为激酶抑制剂的Lck抑制剂进行治疗肿瘤学，可选择与来自NSAIDs、类固醇、DMARDs、免疫抑制剂、生物反应调节剂和抗感染药物中的一个或多个其他药物结合，包括所述Lck抑制剂和所述其他药物的药物组合物，以及利用Lck抑制剂制备用于治疗涉及免疫组分的免疫性疾病或病理条件的制药组合物。
• Use of LCK inhibitors for treatment of immunologic diseases
  申请人：Boehringer Ingelheim Pharma GmbH & Co. KG

  公开号：EP2281561A2

  公开（公告）日：2011-02-09

  The invention relates to a method of treating immunologic diseases or pathological conditions involving an immunologic component using certain Lck inhibitors already known as kinase inhibitors for therapy in oncology, optionally in combination with one or more other drugs selected from NSAIDs, steroids, DMARDs, immunsuppressives, biologic response modifiers and antinfectives, pharmaceutical compositions comprising said Lck inhibitors together with said other drugs, and the use of the Lck inhibitors for the manufacture of a pharmaceutical composition for the treatment of immunologic diseases or pathological conditions involving an immunologic component.

  本发明涉及一种治疗涉及免疫成分的免疫性疾病或病理条件的方法，该方法使用某些已被称为肿瘤学治疗激酶抑制剂的Lck抑制剂，可选择与一种或多种选自非甾体抗炎药、类固醇、DMARDs、免疫抑制剂、生物反应调节剂和抗感染药的其他药物联合使用，药物组合物包含所述Lck抑制剂和所述其他药物，以及使用Lck抑制剂制造用于治疗免疫性疾病或病理条件的药物组合物、生物反应调节剂和抗感染药，由所述 Lck 抑制剂和所述其它药物组成的药物组合物，以及使用 Lck 抑制剂制造用于治疗免疫性疾病或涉及免疫成分的病理状况的药物组合物。
• USE OF LCK INHIBITOR FOR TREATMENT OF IMMUNOLOGIC DISEASES
  申请人：Boehringer Ingelheim Pharma KG

  公开号：EP1530466A2

  公开（公告）日：2005-05-18
• US7989474B2
  申请人：——

  公开号：US7989474B2

  公开（公告）日：2011-08-02
• [EN] USE OF LCK INHIBITOR FOR TREATMENT OF IMMUNOLOGIC DISEASES<br/>[FR] UTILISATION D'INHIBITEUR LCK POUR LE TRAITEMENT D'AFFECTIONS IMMUNOLOGIQUES
  申请人：BOEHRINGER INGELHEIM PHARMA

  公开号：WO2004017948A2

  公开（公告）日：2004-03-04

  The invention relates to a method of treating immunologc diseases or pathological conditions involving an immunologc component using Lck inhibitors already known as kinase inhibitors for therapy in oncology, optionally in combination with one or more other drugs selected from NSAIDs, steroids, DMARDs, immunsuppressive, biologic response modifiers and antinfectives, pharmaceutical compositions comprising said LcK inhibitoir together with said other drugs, and the use of LcK inhibitors for the manufacture of a pharmaceutical composition for the treatment of immunologic diseases or pathological conditions involving an immunologic component.